Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Common Equity: 2011-2025

Historic Common Equity for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $19.0 million.

  • Aytu Biopharma's Common Equity fell 22.31% to $23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year decrease of 22.31%. This contributed to the annual value of $19.0 million for FY2025, which is 31.57% down from last year.
  • As of FY2025, Aytu Biopharma's Common Equity stood at $19.0 million, which was down 31.57% from $27.7 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Common Equity peaked at $137.6 million during FY2021, and registered a low of $19.0 million during FY2025.
  • Moreover, its 3-year median value for Common Equity was $27.7 million (2024), whereas its average is $28.7 million.
  • As far as peak fluctuations go, Aytu Biopharma's Common Equity spiked by 44.79% in 2021, and later slumped by 67.79% in 2022.
  • Aytu Biopharma's Common Equity (Yearly) stood at $137.6 million in 2021, then crashed by 67.79% to $44.3 million in 2022, then fell by 11.17% to $39.4 million in 2023, then dropped by 29.58% to $27.7 million in 2024, then crashed by 31.57% to $19.0 million in 2025.